GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thor Medical ASA (LTS:0R6Y) » Definitions » Valuation Rank

Thor Medical ASA (LTS:0R6Y) Valuation Rank


View and export this data going back to 2015. Start your Free Trial

What is Thor Medical ASA Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Thor Medical ASA Valuation Rank Related Terms

Thank you for viewing the detailed overview of Thor Medical ASA's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Thor Medical ASA Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thor Medical ASA (LTS:0R6Y) » Definitions » Valuation Rank
Comparable Companies
OSL:NYKD OSL:AZT OSL:HBC OSL:ZLNA OSL:LYTIX OSL:EXTX OSL:ONCIN OSL:ABS OSL:SOFTX OSL:BGBIO VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
TRMED:Norway 8NN:Germany
Address
Karenslyst Alle 9C, Oslo, NOR, 0278
Website
https://www.thormedical.no
Thor Medical ASA is a Norway-based biopharmaceutical company. The Company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. The Company has developed a proprietary technology for the manufacturing of radionuclides, alpha-particle emitters from natural resources. The high energy deposition and the short range of alpha particles make it possible to eradicate cancer cells while minimizing damage to nearby healthy cells.